Drug Profile
VB 19038
Alternative Names: VB-19038Latest Information Update: 19 May 2011
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 19 May 2011 Discontinued - Preclinical for HIV infections in USA (unspecified route)
- 18 Jun 2001 No-Development-Reported for HIV infections treatment in USA (Unknown route)
- 03 Nov 1998 Preclinical development for HIV infections treatment in USA (Unknown route)